Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Neoplastic transformation in vitro by mixed beams of high-energy iron ions and protons.

Elmore E, Lao XY, Kapadia R, Swete M, Redpath JL.

Radiat Res. 2011 Sep;176(3):291-302. Epub 2011 Jul 6.

PMID:
21732791
2.

Effect of dose-rate on induction of neoplastic transformation in vitro by low doses of 232 MeV protons.

Elmore E, Lao XY, Kapadia RL, Redpath JL.

Int J Radiat Biol. 2011 Jun;87(6):622-7. doi: 10.3109/09553002.2011.570415.

PMID:
21627566
4.

Comment on "Mammography-oncogenecity at low doses".

Mitchel RE, Redpath JL.

J Radiol Prot. 2009 Sep;29(3):457-9. No abstract available.

PMID:
19810287
5.

Threshold-type dose response for induction of neoplastic transformation by 1 GeV/nucleon iron ions.

Elmore E, Lao XY, Kapadia R, Redpath JL.

Radiat Res. 2009 Jun;171(6):764-70. doi: 10.1667/RR1673.1. Erratum in: Radiat Res. 2009 Sept;172(3):403.

PMID:
19580483
6.

Radiation-induced neoplastic transformation in vitro, hormesis and risk assessment.

Redpath JL, Elmore E.

Dose Response. 2006 Dec 6;5(2):123-30. doi: 10.2203/dose-response.06-010.Redpath.

7.

Suppression of neoplastic transformation in vitro by low doses of low LET radiation.

Redpath JL.

Dose Response. 2006 Nov 27;4(4):302-8. doi: 10.2203/dose-response.06-114.Redpath.

8.

Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer.

Veena MS, Lee G, Keppler D, Mendonca MS, Redpath JL, Stanbridge EJ, Wilczynski SP, Srivatsan ES.

Genes Chromosomes Cancer. 2008 Sep;47(9):740-54. doi: 10.1002/gcc.20576.

9.

Low doses of very low-dose-rate low-LET radiation suppress radiation-induced neoplastic transformation in vitro and induce an adaptive response.

Elmore E, Lao XY, Kapadia R, Giedzinski E, Limoli C, Redpath JL.

Radiat Res. 2008 Mar;169(3):311-8. doi: 10.1667/RR1199.1.

PMID:
18302492
10.

p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest.

Wang XQ, Stanbridge EJ, Lao X, Cai Q, Fan ST, Redpath JL.

Radiat Res. 2007 Dec;168(6):706-15.

PMID:
18088187
11.

Detrimental and protective bystander effects: a model approach.

Schöllnberger H, Mitchel RE, Redpath JL, Crawford-Brown DJ, Hofmann W.

Radiat Res. 2007 Nov;168(5):614-26. Erratum in: Radiat Res. 2008 Apr;169(4):481.

12.

Biometrics and international migration.

Redpath J.

Ann Ist Super Sanita. 2007;43(1):27-35. Review.

13.

Health risks of low photon energy imaging.

Redpath JL.

Radiat Prot Dosimetry. 2006;122(1-4):528-33. Epub 2007 Jan 29. Review.

PMID:
17261539
14.

Development and characteristics of a human cell assay for screening agents for melanoma prevention.

Elmore E, Jain A, Siddiqui S, Tohidian N, Meyskens FL, Steele VE, Redpath JL.

Melanoma Res. 2007 Feb;17(1):42-50.

15.

The effect of dose rate on radiation-induced neoplastic transformation in vitro by low doses of low-LET radiation.

Elmore E, Lao XY, Kapadia R, Redpath JL.

Radiat Res. 2006 Dec;166(6):832-8.

PMID:
17149982
16.

Enhanced biological effectiveness of low energy X-rays and implications for the UK breast screening programme.

Redpath JL, Mitchel RE.

Br J Radiol. 2006 Oct;79(946):854-5; author reply 855-7. No abstract available.

PMID:
16980679
17.

ATR dependent activation of Chk2.

Wang XQ, Redpath JL, Fan ST, Stanbridge EJ.

J Cell Physiol. 2006 Sep;208(3):613-9.

PMID:
16741947
18.

Neoplastic transformation in vitro by low doses of ionizing radiation: role of adaptive response and bystander effects.

Ko M, Lao XY, Kapadia R, Elmore E, Redpath JL.

Mutat Res. 2006 May 11;597(1-2):11-7. Epub 2006 Jan 18.

PMID:
16414089
19.

Neoplastic transformation in vitro induced by low doses of 232 MeV protons.

Elmore E, Lao XY, Ko M, Rightnar S, Nelson G, Redpath J.

Int J Radiat Biol. 2005 Apr;81(4):291-7.

PMID:
16019938
20.

Correction of malignant behavior of tumor cells by traditional Chinese herb medicine through a restoration of p53.

Deng WP, Chao MW, Lai WF, Sun C, Chung CY, Wu CC, Lin IH, Hwang JJ, Wu CH, Chiu WT, Chen CY, Redpath JL.

Cancer Lett. 2006 Feb 28;233(2):315-27.

PMID:
15882924
21.

Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels.

Elmore E, Siddiqui S, Navidi M, Steele VE, Redpath JL.

J Cell Biochem. 2005 Jun 1;95(3):571-88.

PMID:
15786488
22.

Nonlinear response for neoplastic transformation following low doses of low let radiation.

Redpath JL.

Nonlinearity Biol Toxicol Med. 2005 Jan;3(1):113-24. doi: 10.2201/nonlin.003.01.007.

23.

Neoplastic transformation in vitro after exposure to low doses of mammographic-energy X rays: quantitative and mechanistic aspects.

Ko SJ, Liao XY, Molloi S, Elmore E, Redpath JL.

Radiat Res. 2004 Dec;162(6):646-54.

PMID:
15548114
24.

Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G2-phase cells.

Lio YC, Schild D, Brenneman MA, Redpath JL, Chen DJ.

J Biol Chem. 2004 Oct 1;279(40):42313-20. Epub 2004 Jul 29.

25.
26.

Homozygous deletions within the 11q13 cervical cancer tumor-suppressor locus in radiation-induced, neoplastically transformed human hybrid cells.

Mendonca MS, Farrington DL, Mayhugh BM, Qin Y, Temples T, Comerford K, Chakrabarti R, Zainabadi K, Redpath JL, Stanbridge EJ, Srivatsan ES.

Genes Chromosomes Cancer. 2004 Apr;39(4):277-87.

PMID:
14978789
27.

Mechanisms of suppression of neoplastic transformation in vitro by low doses of low LET radiation.

Pant MC, Liao XY, Lu Q, Molloi S, Elmore E, Redpath JL.

Carcinogenesis. 2003 Dec;24(12):1961-5. Epub 2003 Sep 26.

PMID:
14514653
28.

The human epithelial cell cytotoxicity assay for determining tissue specific toxicity: method modifications.

Elmore E, Siddiqui S, Desai N, Moyer MP, Steele VE, Redpath JL.

Methods Cell Sci. 2002;24(4):145-53.

PMID:
12843703
29.

Low doses of diagnostic energy X-rays protect against neoplastic transformation in vitro.

Redpath JL, Lu Q, Lao X, Molloi S, Elmore E.

Int J Radiat Biol. 2003 Apr;79(4):235-40.

PMID:
12775447
30.

Differential effectiveness of solar UVB subcomponents in causing cell death, oncogenic transformation and micronucleus induction in human hybrid cells.

Bettega D, Calzolari P, Doneda L, Belloni F, Tallone L, Redpath JL.

Int J Radiat Biol. 2003 Mar;79(3):211-6.

PMID:
12745886
31.
32.
33.

Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer.

Srivatsan ES, Chakrabarti R, Zainabadi K, Pack SD, Benyamini P, Mendonca MS, Yang PK, Kang K, Motamedi D, Sawicki MP, Zhuang Z, Jesudasan RA, Bengtsson U, Sun C, Roe BA, Stanbridge EJ, Wilczynski SP, Redpath JL.

Oncogene. 2002 Aug 15;21(36):5631-42.

34.

Championing health care for children and youth: Ensuring Canada's future.

Holland J, Davis MA, Redpath J.

Paediatr Child Health. 2002 Apr;7(4):231-2. No abstract available.

35.

Comparative tissue-specific toxicities of 20 cancer preventive agents using cultured cells from 8 different normal human epithelia.

Elmore E, Luc TT, Steele VE, Redpath JL.

In Vitr Mol Toxicol. 2001 Fall;14(3):191-207.

PMID:
11846992
37.
38.

Solar UV radiation: differential effectiveness of UVB subcomponents in causing cell death, micronucleus induction and delayed expression of heritable damage in human hybrid cells.

Bettega D, Calzolari P, Belloni F, Di Lena F, Genchi S, Lupi M, Massariello P, Orsini S, Tallone L, Tomasoni D, Ubezio P, Redpath JL.

Int J Radiat Biol. 2001 Sep;77(9):963-70.

PMID:
11576456
39.

Chemoprevention by difluoromethylornithine: correlation of an in vitro human cell assay with human clinical data for biomarker modulation.

Elmore E, Stringer DE, Steele VE, Gerner EW, Redpath JL.

Anticancer Res. 2001 Mar-Apr;21(2A):1163-5.

PMID:
11396157
40.

Interstitial deletion of 11q13 sequences in HeLa cells.

Srivatsan ES, Bengtsson U, Manickam P, Benyamini P, Chandrasekharappa SC, Sun C, Stanbridge EJ, Redpath JL.

Genes Chromosomes Cancer. 2000 Oct;29(2):157-65.

PMID:
10959095
41.
42.

Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data.

Elmore E, Luc TT, Li HR, Buckmeier JA, Steele VE, Kelloff GJ, Redpath JL.

Anticancer Res. 2000 Jan-Feb;20(1A):27-32.

PMID:
10769631
43.

The human epithelial cell cytotoxicity assay for determining tissue specific toxicity.

Elmore E, Luc TT, Steele VE, Kelloff GJ, Redpath JL.

Methods Cell Sci. 2000 Mar;22(1):17-24. Review.

PMID:
10650329
44.

Prolonged cell cycle arrest in irradiated human diploid skin fibroblasts: the role of nutrient deprivation.

DeSimone JN, Dolezalova H, Redpath JL, Stanbridge EJ.

Radiat Res. 2000 Feb;153(2):131-43.

PMID:
10629612
45.

Differential gene expression in tumorigenic and nontumorigenic HeLa x normal human fibroblast hybrid cells.

Tsujimoto H, Nishizuka S, Redpath JL, Stanbridge EJ.

Mol Carcinog. 1999 Dec;26(4):298-304.

PMID:
10569806
46.

In vitro chemopreventive efficacy screening using human keratinocytes and the in vivo data correlation.

Elmore E, Sun C, Li HR, Wyatt GP, Buckmeier JA, Steele VE, Kelloff GJ, Redpath JL.

Anticancer Res. 1999 Mar-Apr;19(2A):909-18.

PMID:
10368633
47.

Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction.

Suzuki T, Iwazaki A, Katagiri H, Oka Y, Redpath JL, Stanbridge EJ, Kitagawa T.

Eur J Biochem. 1999 Jun;262(2):534-40.

48.

Gap junction expression following UVC-induced neoplastic transformation in human hybrid cell lines.

Ehring GR, Antoniono RJ, Redpath JL.

Carcinogenesis. 1998 Dec;19(12):2085-93.

PMID:
9886561
49.

Reduction of caveolin-1 expression in tumorigenic human cell hybrids.

Suzuki T, Suzuki Y, Hanada K, Hashimoto A, Redpath JL, Stanbridge EJ, Nishijima M, Kitagawa T.

J Biochem. 1998 Aug;124(2):383-8.

50.

Restored gap junctional communication in non-tumorigenic HeLa-normal human fibroblast hybrids.

de Feijter-Rupp HL, Hayashi T, Kalimi GH, Edwards P, Redpath JL, Chang CC, Stanbridge EJ, Trosko JE.

Carcinogenesis. 1998 May;19(5):747-54.

PMID:
9635859

Supplemental Content

Loading ...
Support Center